Experimental drug slows tumor growth

	Tweet

Amgen Inc. and Abgenix Inc. said on Thursday a late-stage study found its experimental drug panitumumab helped slow tumor progression in patients with advanced Colon cancer who had failed multiple other therapies.

In the 463-patient trial, patients who received panitumumab every two weeks showed a 46 percent decrease in tumor progression rate versus those who received best supportive care alone, the companies said.

The result was better than the pre-set goal of a 33 percent decrease in tumor progression, they said.

"We are very encouraged by the results of this pivotal study and what panitumumab could mean for patients with advanced Colorectal cancer,” said Bill Ringo, president and chief executive officer of Abgenix.

The news sent shares of Amgen and Abgenix sharply higher while dragging down shares of ImClone Systems Inc., maker of a rival drug. 

RELATED STORIES:
Smoking can double risk of colorectal polyps   Genetic ID of Marker in Lymph Nodes May be Linked to Colorectal Cancer Recurrence Risk   Risk of cancer   Hormone Therapy Offers Potential Protective Effect Against Colon Cancer In Older Women   Colon cancer hits blacks at a younger age   Negative screening colonoscopy need not be repeated   Consistent exercise associated with lower risk of colon cancer death   Gut bacteria could be key indicator of colon cancer risk   Digestive Health Experts Urge More Americans to Get Screened for Colorectal Cancer   Colonoscopy Prep Harder on Women than Men   Most Adults Don’t Realize Activity Lowers Colon Cancer Risk   Curry-derived Molecules Might be Too Spicy for Colorectal Cancers   Surgery Complications Linked to Chemotherapy Delay   HBV infection decreases risk of liver metastasis in colorectal cancer patients   Genetic Link Uncovered in Disparate Colon Cancer Death   Diet, smoking, exercise key in colon cancer risk   ‘Western’ diet linked to increased risk of colon cancer recurrence   Apple pectin, apple juice extracts shown to have anticarcinogenic effects on colon   Shifting a Paradigm: a Molecular Approach to Staging Colorectal Cancer   Water method for unsedated colonoscopy; interval between prep and colonoscopy predicts prep quality   Common Bone Drugs May Reduce Colon Cancer Risk   March is Colorectal Cancer Awareness Month

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]